Expansion of the ophthalmology business through the acquisition of 日本点眼薬研究所 as a subsidiary
First written in FY2020-Q2. 7 of 11 entries say "Cited as achieved", first in FY2021-Q1. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1RestatedAnnual report
「Among the domestic group companies, 天藤製薬㈱ and クオリテックファーマ㈱ contributed to the increase in revenue.」
The contribution of 天藤製薬 and クオリテックファーマ to higher domestic sales has been disclosed, reconfirming the contribution of the ophthalmology- and pharmaceutical-related subsidiaries after their acquisition. - FY2026-H1RestatedAnnual report
「Among the domestic group companies, 天藤製薬㈱ and ロートニッテン㈱ contributed to the increase in revenue.」
The contribution of ロートニッテン㈱, which originated as 日本点眼薬研究所, and 天藤製薬㈱ to higher sales in the domestic business has been reconfirmed. - FY2025-H1Cited as achievedAnnual report
「Among the domestic group companies, ロートニッテン㈱ and クオリテックファーマ㈱ contributed to the increase in revenue.」
The contribution to higher sales from domestic group companies in the ophthalmology field, including ロートニッテン㈱, which originated as 日本点眼薬研究所, has been reported as an actual result. - FY2024Cited as achievedAnnual report
「Among the domestic group companies, ロートニッテン㈱ and 天藤製薬㈱, whose principal product is “ボラギノール®,” also contributed to the increase in revenue.」
The contribution to higher domestic sales after the acquisition of 日本点眼薬研究所 by ロートニッテン and of 天藤製薬 has been reported as an actual result. - FY2022-Q2Cited as achievedAnnual report
「In addition, クオリテックファーマ㈱ and ㈱日本点眼薬研究所 contributed to the increase in revenue.」
The contribution of 日本点眼薬研究所, which became a subsidiary at the end of the previous consolidated fiscal year, to higher sales during the cumulative second quarter has been reported as an actual result. - FY2021Cited as achievedAnnual report
「However, sales of ㈱日本点眼薬研究所, which became a subsidiary at the end of the previous consolidated fiscal year, contributed to the increase in revenue.」
The full-year contribution to sales after the acquisition of 日本点眼薬研究所 has been reported as an actual result. - FY2021-Q3Cited as achievedAnnual report
「株式会社日本点眼薬研究所 also performed well.」
The fact that 日本点眼薬研究所, which became a subsidiary at the end of the previous consolidated fiscal year, performed well during the cumulative third quarter has been reported as an actual result. - FY2021-Q2Cited as achievedAnnual report
「In addition to Nihon Eye Research Laboratories Co., Ltd., the subsidiaries engaged in contract pharmaceutical development and manufacturing also performed well.」
The contribution to sales and the business from 日本点眼薬研究所 and other companies that became subsidiaries at the end of the previous consolidated fiscal year has been reported as an actual result. - FY2021-Q1Cited as achievedAnnual report
「Meanwhile, sales from 日本点眼薬研究所, which became a subsidiary at the end of the previous consolidated fiscal year, contributed to results.」
The contribution to sales after the acquisition of 日本点眼薬研究所 has been reported as an actual result. - FY2020AchievedAnnual report
「Business combination date: 2 March 2020 (deemed acquisition date: 31 March 2020) Voting rights acquired: 100%」
On 2 March 2020, the Company acquired 株式会社日本点眼薬研究所 through a share acquisition and made it a subsidiary, acquiring 100% of the voting rights. The plan to combine technologies such as PF Delami Containers with the OTC eye-drop business and expand into the medical ophthalmology markets in Japan and overseas moved into the execution phase. - FY2020-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 13 November 2019, the Company resolved to acquire the shares of 株式会社日本点眼薬研究所 and make it a subsidiary. The aim is to develop and introduce outstanding ophthalmic products unlike any others and expand the business into ophthalmology markets in Japan and overseas by combining the technology behind the “PF Delami Container” and many ophthalmic eye drops owned by 株式会社日本点眼薬研究所 with the Company's strengths as a leader in OTC eye drops. Planned acquisition date: 1 March 2020. Ownership interest after acquisition: 100%.」
The Company first disclosed its plan to make 日本点眼薬研究所 a wholly owned subsidiary on 1 March 2020, combine its container and ophthalmic eye-drop technologies with the Company's OTC eye-drop business, and expand in the ophthalmology markets in Japan and overseas.